SkinMedica Closes $11 Million Round of Financing

SkinMedica, Inc., a specialty pharmaceutical company focused on developing, acquiring and commercializing products that treat dermatologic conditions and diseases and improve the appearance of skin, announced today the closing of an $11 million private placement of its Series E-1 preferred stock. Montagu Newhall Associates, a new investor, led the round and existing investors Domain Associates, Apax Partners, Perseus-Soros Biopharmaceutical Fund, HealthCare Ventures, EuclidSR Partners and Montreux Equity Partners also participated.

Tom Insley
SkinMedica, Inc.
1-866-867-0110
tinsley@skinmedica.com

About SkinMedica
SkinMedica is a privately held specialty pharmaceutical company marketing both prescription and cosmeceutical dermatology products. SkinMedica's EpiQuin® Micro (4% Hydroquinone) treats melasma and postinflammatory hyperpigmentation, VANIQA® (eflornithine hydrochloride) Cream, 13.9%, is the only FDA-approved prescription product for the treatment of unwanted facial hair in women, and NeoBenz™ Micro, which contains a patented gradual-release formulation of benzoyl peroxide, treats acne. The company's full line of cosmeceutical products, which is sold through physicians, includes TNS Recovery Complex® with NouriCel-MD® to help improve the health and appearance of aging skin. SkinMedica is based in Carlsbad, California. For more information, visit: www.skinmedica.com.

SkinMedica cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by SkinMedica that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in SkinMedica's business due to a number of factors, including: we and our products face significant competition; and unexpected adverse side effects or inadequate therapeutic efficacy of our products could delay or prevent product development or commercialization, or could result in recalls or product liability claims. All forward-looking statements are qualified in their entirety by this cautionary statement and SkinMedica undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

VANIQA®, EpiQuin® Micro, TNS Recovery Complex®, NouriCel-MD®, SkinMedica® and NeoBenz® Micro are trademarks of SkinMedica, Inc.